Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 360° synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of schizophrenia
3.2.1.2 Advancements in drug delivery systems
3.2.1.3 Government initiatives and support
3.2.2 Industry pitfalls & challenges
3.2.2.1 Side effects of drugs
3.2.2.2 Stringent regulatory scenario
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.5.1 Core technologies
3.5.2 Adjacent technologies
3.6 Future market trends
3.7 Pipeline analysis
3.8 Porter’s analysis
3.9 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Therapeutic Class, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Second generation antipsychotics
5.3 Third generation antipsychotics
5.4 Other therapeutic classes
Chapter 6 Market Estimates and Forecast, By Type, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Paranoid schizophrenia
6.3 Hebephrenic schizophrenia
6.4 Catatonic schizophrenia
6.5 Undifferentiated schizophrenia
6.6 Other types
Chapter 7 Market Estimates and Forecast, By Treatment, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Oral
7.3 Injectable
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 AbbVie Inc.
10.2 Alkermes Public Limited Company
10.3 AstraZeneca PLC
10.4 Bristol-Myers Squibb Company
10.5 Eli Lilly and Company
10.6 H. Lundbeck A/S
10.7 Intra-Cellular Therapies, Inc.
10.8 Johnson & Johnson
10.9 Otsuka Pharmaceutical Co., Ltd.
10.10 Pfizer Inc.
10.11 Recordati Industria Chimica e Farmaceutica S.p.A
10.12 SUMITOMO PHARMA CO., LTD
10.13 Takeda Pharmaceutical Company Limited
10.14 Teva Pharmaceutical Industries Limited
10.15 Vanda Pharmaceuticals Inc.
